2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117390
    FR-181074 184147-65-7 98%
    FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the researches of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction.
    FR-181074
  • HY-117436
    R(+)-6-Bromo-APB hydrobromide 139689-19-3 98%
    R(+)-6-Bromo-APB hydrobromide is a dopamine (DA) agonist. R(+)-6-Bromo-APB hydrobromide increased the expression of µ opioid receptor (MOR) mRNA in the nucleus accumbens.
    R(+)-6-Bromo-APB hydrobromide
  • HY-117489
    Julibrine II 142628-29-3 98%
    Julibrine II is a pyridoxine derivative that can be isolated from the bark of the Albizzia julibrissin DURAZZ. Julibrine II has the ability to induce cardiac arrhythmias.
    Julibrine II
  • HY-117494
    Flumethiazide 148-56-1 98%
    Flumethiazide (NSC 44626) is an orally active diuretic agent. Flumethiazide has marked diuretic and natruretic effects with significant effects on Sodium, Chloride and water but not on potassium excretion. Flumethiazide can be used for cardiac diseases like essential hypertension research.
    Flumethiazide
  • HY-117528
    WAY-123398 138490-53-6 98%
    WAY-123398 is a class III antiarrhythmic agent. WAY-123398 is a selective blocker of the delayed rectifier K+ current.
    WAY-123398
  • HY-117537
    XR 5118 hydrochloride 174766-49-5 98%
    XR 5118 hydrochloride is an inhibitor of plasminogen activator inhibitor 1 (PAI-1) (IC50: 12 µM). XR5118 binds to PAI-1 and reduces plasma PAI-1 activity levels. XR5118 hydrochloride promotes endogenous thrombolysis and inhibits thrombus accretion. XR 5118 hydrochloride can be used for research of cancer and thrombotic disease.
    XR 5118 hydrochloride
  • HY-117555
    4010B-30 1415477-76-7 98%
    4010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE-/- mice.
    4010B-30
  • HY-117568
    A-80b 135561-94-3 98%
    A-80b is a pyridazino[4,5-b]indole derivate. A 80b showsantihypertensive activity and can be used for study of Arterial hypertension.
    A-80b
  • HY-117574
    SB 207710 148703-08-6 98%
    SB 207710 is a highly selective antagonist of the 5-HT4 receptor that has been shown to effectively block the positive inotropic effect induced by serotonin in human right atrial appendage preparations.
    SB 207710
  • HY-117618
    KF-14124 134186-26-8 98%
    KF-14124, an orally active organic nitrate, a long-acting vasodilator with highly selective venous dilating action. KF-14124 is used in the study for angina pectoris. KF-14124 shows good oral inhibition of lysine-vasopressin induced coronary vasospasm with a potency.
    KF-14124
  • HY-117641
    CP 81282 121584-61-0 98%
    CP 81282 is a tripeptide aspartic protease inhibitor, with an IC50 of 1 nM against human renin and an IC50 of 11 nM against endopeptidase. CP 81282 is applicable to the research of hypertension.
    CP 81282
  • HY-117703
    CVS 738 151275-15-9 98%
    CVS 738 is the desmethyl form of CVS 1123, which is also the major active metabolite of CVS 1123.
    CVS 738
  • HY-117712
    LG 6-101 132798-26-6 98%
    LG 6-101 is an orally active antiarrhythmic agent. LG 6-101 shows strong antiarrhythmic effects in a coronary-artery-ligation model of rats, better than Propafenone (HY-B0432). LG 6-101 also delays the occurence of ventricular premature beat (VPB)'s and has protective effects against cardiac arrest caused by aconitine.
    LG 6-101
  • HY-117715
    CK-3197 132523-92-3 98%
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure.
    CK-3197
  • HY-117745
    DS-1040 1335138-62-9 98%
    DS-1040 is a low-molecular-weight imidazole derivative. DS-1040 is an inhibitor of the activated thrombin-activatable fibrinolysis (TAFIa). DS-1040 can promote fibrinolysis through suppressing TAFIa activity. DS-1040 can be studied in thrombolytic disease research.
    DS-1040
  • HY-117765
    RS-5773 129173-57-5 98%
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-117811
    (R,R)-MK 287 143490-81-7 98%
    (R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg).
    (R,R)-MK 287
  • HY-117814
    BMS-187308 153624-15-8 98%
    BMS-187308 is an orally active endothelin-A (ETA) antagonist, with Kis of 4.7 nM for ETA and 1.7 μM for ETB. BMS-187308 inhibits the pressor response to ET-1 (ED25: 1.2 µmol/kg; iv). BMS-187308 is a suitable tool for investigating the role of endothelin.
    BMS-187308
  • HY-117928
    BRL 55834 131899-25-7 98%
    BRL 55834 is an orally and potent potassium channel activator. BRL 55834 exhibits great bronchodilator potency but reduces tendency to lower arterial blood pressure. BRL 55834 has the potential to use as a bronchodilator.
    BRL 55834
  • HY-117966
    Bibn 140 145301-79-7 98%
    Bibn 140 is a pyridine derivative substituted with a benzene ring, which has high affinity (Ki: 12 nM) and selectivity for M2 mAChR receptors over M1 receptors.
    Bibn 140
Cat. No. Product Name / Synonyms Application Reactivity